Celgene/Presage Collaboration To Enable Comparisons Of Drug Combos In Living Tumors

Celgene is paying $13 million to gain access to Presage Biosciences’ technology platform in a collaboration that will save significant time in studying combinations of oncology drugs for solid tumors.